Opendata, web and dolomites

BADGER SIGNED

CalScreener® – an innovative device for Bacterial Analysis and Diagnostics through Growth and Energy-release in Real-time

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BADGER project word cloud

Explore the words cloud of the BADGER project. It provides you a very rough idea of what is the project "BADGER" about.

rapid    amr    though    assays    infections    validate    antibiotic    service    lay    healthcare    decisions    speed    patients    specificity    mic    multichannel    sensitivity    causing    cellular    antimicrobial    commercializing    intend    resistant    clinically    sepsis    lack    tool    provides    contributes    overuse    near    tools    accuracy    pure    ill    micro    vitro    combination    paradigm    meet    patient    smartly    sold    assay    cell    misuse    symcel    suitable    hetero    foundation    critically    treatment    isothermal    first    susceptibility    diagnoses    personalized    device    broad    diagnostic    resistance    line    readily    extensively    bioenergetics    solution    inappropriate    introduce    commercial    calorimetry    daily    perform    clinical    validating    settings    pharmaceutical    date    efficient    break    time    setting    accurate    calorimetric    stewardship    prescribing    ast    gt    combat    badger    clinicians    designed    diagnostics    segment    calscreenertm    correct    antibiotics    strains    packaged    redefine   

Project "BADGER" data sheet

The following table provides information about the project.

Coordinator
SYMCEL AB 

Organization address
address: DOMNARVSGATAN 4
city: SPANGA
postcode: 163 53
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Project website https://symcel.com/h2020-ast-combination-testing/
 Total cost 3˙572˙567 €
 EC max contribution 3˙572˙567 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2017
 Duration (year-month-day) from 2017-12-01   to  2020-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SYMCEL AB SE (SPANGA) coordinator 3˙572˙567.00

Map

 Project objective

SymCel provides a novel cell-based assay tool for real-time cellular bioenergetics measurements. Our key product, the calScreenerTM, is the first multichannel calorimetric system specifically developed for cell-based assays, which to date has been sold to the pharmaceutical research segment only. Even though calorimetry is a highly advanced research tool, it is considered not suitable for broad scale uptake into daily clinical practice. Through the BADGER project we intend to break this paradigm by validating and commercializing an in vitro diagnostic tool, that is based on isothermal micro calorimetry, for determining MIC for antimicrobial susceptibility testing (AST) of hetero-resistant sepsis causing strains. By providing a tool for the easy, correct and timely diagnoses of hetero-resistant and extensively resistant infections, we will redefine the commercial application segment for calorimetry systems (from pure research settings -> near patient diagnostics) and take AST to a new level of accuracy and speed. The clinical importance of AST is increasing in line with the growing concerns over antimicrobial-resistance (AMR) and the misuse of antibiotics. Lack of a rapid, low-cost and readily available solution contributes to the inappropriate prescribing and overuse of antibiotics. Clinicians are in need of an accurate and rapid diagnostic test to increase antibiotic stewardship, introduce combination treatment for critically ill patients and help combat AMR. The calScreenerTM will meet the users’ needs by providing a reliable diagnostic tool with high speed, specificity, and sensitivity in a smartly designed and packaged device with the tools available to perform testing in a near-patient setting. In all, the Phase 2 project will lay the foundation to clinically validate the calScreenerTM which will improve diagnostic decisions, provide a higher service level for patients, combat AMR and allow for more personalized and cost-efficient approaches to healthcare.

 Deliverables

List of deliverables.
Project subpage on corporate website Websites, patent fillings, videos etc. 2020-03-04 09:46:23
Ethics approval for Clinical study no. 2 Documents, reports 2020-03-04 09:46:23
Ethics approval for Clinical study no. 1 Documents, reports 2020-03-04 09:46:23
Ethics approval for Clinical study no. 3 Documents, reports 2020-03-04 09:46:23

Take a look to the deliverables list in detail:  detailed list of BADGER deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BADGER" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BADGER" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More  

INTE-AFRICA (2019)

Integrating and decentralising diabetes and hypertension services in Africa

Read More  

FAIR (2020)

FLAGELLIN AEROSOL THERAPY AS AN IMMUNOMODULATORY ADJUNCT TO THE ANTIBIOTIC TREATMENT OF DRUG-RESISTANT BACTERIAL PNEUMONIA

Read More